- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01805895
A Pilot Study of Minocycline in Intracerebral Hemorrhage Patients (MACH)
March 28, 2018 updated by: Jeffrey Switzer, Augusta University
Minocycline in Acute Cerebral Hemorrhage (MACH) Trial
The MACH Trial is a pilot study of 400mg minocycline over five days in acute intracerebral hemorrhage patients.
The study will evaluation the safety and efficacy of minocycline in intracerebral hemorrhage patients.
Study Overview
Detailed Description
MACH is a randomized trial of minocycline in intracerebral hemorrhage.
24 total subjects will be randomly assigned to minocycline or control (1:1).
The first dose will be given intravenously.
Subsequent doses will be given orally every 24 hours for a total of five doses.
The study will test to see if the medication is safe in intracerebral hemorrhage.
The pharmacokinetics of minocycline in intracerebral hemorrhage will be determined and the impact of minocycline on blood biomarkers.
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- Georgia Health Sciences University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 years of age or older.
- Intracerebral hemorrhage documented by CT scan
- The first dose of the drug can be administered within 12 hours of time last known to be at baseline
Exclusion Criteria:
- Allergy to tetracycline antibiotics
- Pregnancy or suspected pregnancy (pregnancy test will be done on women of child-bearing potential)
- Hepatic and/or renal insufficiency (LFT's >3x upper limit of normal; Creatinine >2mg/dL)
- History of intolerance to minocycline
- National Institutes of Health Stroke Scale score of 4 or less
- Glasgow Coma Scale score of 5 or less
- Surgical evacuation of hematoma planned within 24 hours
- Secondary intracerebral hemorrhage resulting from trauma, arteriovenous malformation, aneurysm, tumor or other causes
- Thrombocytopenia (platelet count <75,000/mm3) or coagulopathy (INR >1.4)
- Previously not independent (prestroke modified Rankin scale score >2)
- Suspected of not being able to comply with the study protocol
- Unlikely to be available for 90 day follow-up
- Pre-existing Do Not Resuscitate (DNR) order or indication that a new DNR order will be implemented within the first 48 hours of hospitalization
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Minocycline
This intervention arm will receive a total of 5 doses of Minocycline.
Dose 1 of Minocycline will be 400mg IV within 12-hours of onset of symptoms.
Dose 2 of Minocycline will be 400mg oral, given daily on days 2-5 .
Each dose is 24 hours apart.
|
This arm will receive a total of 5 doses of minocycline.
Dose 1 will be 400mg IV within 12-hours of onset of symptoms.
Dose 2 will be 400mg oral, given daily on days 2-5 .
Each dose is 24 hours apart.
Other Names:
|
No Intervention: Control
This arm will not receive any minocycline.
This arm will receive standard of care treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Modified Rankin Scale
Time Frame: 90 days
|
A blinded assessor will perform the modified Rankin Scale (this is the full scale name) after 90 days.
This will serve as our efficacy endpoint.
The scale measures function.
It ranges from 0 to 6 with zero reflecting no disability, 1 to 5 increasing degrees of disability and 6 death.
Lower numbers reflect preferred outcome.
There are no sub scales.
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety Assessment
Time Frame: 90 days
|
Adverse events will be asses for 90 days.
This will serve as our safety endpoint.
|
90 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Jeffrey A Switzer, DO, Augusta University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2013
Primary Completion (Actual)
December 1, 2016
Study Completion (Actual)
December 1, 2016
Study Registration Dates
First Submitted
March 5, 2013
First Submitted That Met QC Criteria
March 5, 2013
First Posted (Estimate)
March 6, 2013
Study Record Updates
Last Update Posted (Actual)
April 26, 2018
Last Update Submitted That Met QC Criteria
March 28, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00000718
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intracerebral Hemorrhage
-
Wake Forest University Health SciencesActive, not recruitingStroke Hemorrhagic | Intracerebral Hemorrhage | Cerebral Edema | Intracerebral Hemorrhage, Hypertensive | Intracerebral Hemorrhage IntraparenchymalUnited States
-
Tongji HospitalUnknown
-
Huazhong University of Science and TechnologyUnknownHypertensive Intracerebral HemorrhageChina
-
Huazhong University of Science and TechnologyUnknownHypertensive Intracerebral HemorrhageChina
-
Beijing Tiantan HospitalBeijing Friendship Hospital; RenJi Hospital; Qilu Hospital of Shandong University and other collaboratorsRecruitingSpontaneous Intracerebral HemorrhageChina
-
University Hospital, Basel, SwitzerlandSwiss Heart FoundationActive, not recruitingIntracerebral Hemorrhage (ICH)Switzerland
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
AegisCN LLCCompletedIntracerebral Hemorrhage (ICH)United States
-
CellMed AG, a subsidiary of BTG plc.TerminatedIntracerebral Hemorrhage (ICH)Germany
-
Tang-Du HospitalRecruitingIntracerebral Hemorrhage;Circulating ExosomesChina
Clinical Trials on Minocycline
-
Journey Medical CorporationDr. Reddy's Laboratories LimitedCompleted
-
State University of New York - Downstate Medical...RecruitingAsthma | Allergic RhinitisUnited States
-
Central South UniversityCompleted
-
OraPharmaCompleted
-
Johns Hopkins UniversityMakerere UniversityTerminatedHIV Infections | HIV-associated Cognitive ImpairmentUganda
-
Rempex (a wholly owned subsidiary of Melinta Therapeutics...Innovative Medicines Initiative; Universitätsklinikum KölnTerminatedRenal Insufficiency, Chronic | Healthy Subjects | Renal Insufficiency, AcuteGermany
-
University of PittsburghTerminated
-
Ain Shams Universityfaculty of pharmacy Tanta UniversityNot yet recruiting
-
University of South FloridaCompleted
-
Beijing Tiantan HospitalNeuroDawn Pharmaceutical Co., Ltd.RecruitingIschemic Stroke, AcuteChina